C-reactive protein and cerebral small-vessel disease: An opportunity to reassess small-vessel disease physiopathology?

Circulation

Volumn 112, Issue 6, 2005, Pages 781-785

  Di Napoli, Mario ^a,b   Papa, Francesca ^b  

^a SAN CAMILLO DE LELLIS HOSPITAL   (Italy)

^b SMDN   (Italy)

Author keywords

C reactive protein; Cerebrovascular disorders; Editorials; Inflammation; Leukoaraiosis

Indexed keywords

I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; TUMOR NECROSIS FACTOR ALPHA;

BRAIN BLOOD VESSEL; BRAIN INFARCTION; CEREBROVASCULAR DISEASE; CORRELATION ANALYSIS; EDITORIAL; HEART INFARCTION; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; SMALL VESSEL VASCULITIS; STROKE; WHITE MATTER;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CEREBRAL INFARCTION; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISORDERS; HUMANS; MICROCIRCULATION;

EID: 20444414250     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/CIRCULATIONAHA.104.516237     Document Type: Editorial

References (32)

1. Bryan RN, Wells SW, Miller TJ, Elster AD, Jungreis CA, Poirier VC, Lind BK, Manolio TA. Infarctlike lesions in the brain: prevalence and anatomic characteristics at MR imaging of the elderly: data from the Cardiovascular Health Study. Radiology. 1997;202:47-54.
2. Breteler MM, van Swieten JC, Bots ML, Grobbee DE, Claus JJ, van den Hout JH, van Harskamp F, Tanghe HL, de Jong TT, van Gijn J, Hofman A. Cerebral white matter lesions, vascular risk factors, and cognitive function in a population-based study: the Rotterdam Study. Neurology. 1994;44:1246-1252.
3. Hachinski VC, Potter P, Merskey H. Leuko-araiosis. Arch Neurol. 1987;44:21-23.
4. van Dijk EJ, Prins ND, Vermeer SE, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MMB. C-reactive protein and cerebral small-vessel disease: the Rotterdam Scan Study. Circulation. 2005;112:900-905.
5. Libby P. Atherosclerosis: the new view. Sci Am. 2002;286:46-55.
6. Di Napoli M, Papa F. Clinical application of C-reactive protein in stroke prevention: the bright and the dark sides of the moon. Exp Rev Neurother. 2004;4:613-622.
7. Takahashi K, Kobayashi S, Matui R, Yamaguchi S, Yamashita K. The differences of clinical parameters between small multiple ischemic lesions and single lesion detected by diffusion-weighted MRI. Acta Neurol Scand. 2002;106:24-29.
8. Dong Y, Hassan A, Zhang Z, Huber D, Dalageorgou C, Markus HS. Yield of screening for CADASIL mutations in lacunar stroke and leukoaraiosis. Stroke. 2003;34:203-205.
9. Baumgartner RW, Sidler C, Mosso M, Georgiadis D. Ischemic lacunar stroke in patients with and without potential mechanism other than small-artery disease. Stroke. 2003;34:653-659.
10. Pantoni L, Garcia JH. Pathogenesis of leukoaraiosis: a review. Stroke. 1997;28:652-659.
11. Lammie GA. Hypertensive cerebral small vessel disease and stroke prevention. Brain Pathol. 2002;12:358-370.
12. Tomimoto H, Akiguchi I, Ohtani R, Yagi H, Kanda M, Shibasaki H, Yamamoto Y. The coagulation-fibrinolysis system in patients with leukoaraiosis and Binswanger disease. Arch Neurol. 2001;58:1620-1625.
13. Pullicino PM. Pathogenesis of lacunar infarcts and small deep infarcts. Adv Neurol. 1993;62:125-140.
14. Räihä I, Tarvonen S, Kurki T, Rajala T, Sourander L. Relationship between vascular factors and white matter low attenuation of the brain. Acta Neurol Scand. 1993;87:286-289.
15. Matsushita K, Kuriyama Y, Nagatsuka K, Nakamura M, Sawada T, Omae T. Periventricular white matter lucency and cerebral blood flow autoregulation in hypertensive patients. Hypertension. 1994;23:568.
16. Kantachuvesiri S, Fleming S, Peters J, Peters B, Brooker G, Lammie GA, McGrath I, Kotelevtsev Y, Mullins JJ. Controlled hypertension, a transgenic toggle switch reveals differential mechanisms underlying vascular disease. J Bioi Chem. 2001;276:36727-36733.
17. Veniant M, Menard J, Bruneval P, Morley S, Gonzales MF, Mullins JJ. Vascular damage without hypertension in transgenic rats expressing prorenin exclusively in the liver. J Clin Invest. 1996;98:1966-1970.
18. Gibbons GH, Dzau VJ. The emerging concept of vascular remodelling. N Engl J Med. 1994;330:1431-1438.
19. Mervaala EM, Muller DN, Park JK, Schmidt F, Lohn M, Breu V, Dragun D, Ganten D, Haller H, Luft FC. Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension. Hypertension. 1999;33:389-395.
20. Parissis JT, Korovesis S, Giazitzoglou E, Kalivas P, Katritsis D. Plasma profiles of peripheral monocyte-related inflammatory markers in patients with arterial hypertension: correlations with plasma endothelin-1. Int J Cardiol. 2002;83:13-21.
21. McFarlane SI, Kumar A, Sowers JR Mechanisms by which angiotensin- converting enzyme inhibitors prevent diabetes and cardiovascular disease. Am J Cardiol. 2003;91:30H-37H.
22. Nichols TC. NF-kappaB and reperfusion injury. Drug News Perspect. 2004;17:99-104.
23. Herrmann J, Ciechanover A, Lerman LO, Lerman A. The ubiquitin-proteasome system in cardiovascular diseases-a hypothesis extended. Cardiovasc Res. 2004;61:11-21.
24. Di Napoli M, Papa F. Inflammation, blood pressure, and stroke: an opportunity to target primary prevention? Curr Hypertens Rep. 2005;7:44-51.
25. Hassan A, Hunt BJ, O'Sullivan M, Bell R, D'Souza R, Jeffery S, Bamford JM, Markus HS. Homocysteine is a risk factor for cerebral small vessel disease, acting via endothelial dysfunction. Brain. 2004;127:212-219.
26. Hassan A, Gormley K, O'Sullivan M, Knight J, Sham P, Vallance P, Bamford J, Markus H. Endothelial nitric oxide gene haplotypes and risk of cerebral small-vessel disease. Stroke. 2004;35:654-659.
27. Kimoto-Kinoshita S, Ishida S, Tomura TT. Decrease of endothelial nitric oxide synthase in stroke-prone spontaneously hypertensive rat cerebral cortex. Neurosci Lett. 2000;288:103-106.
28. Kawashima S, Yamashita T, Miwa Y, Ozaki M, Namiki M, Hirase T, Inoue N, Hirata K, Yokoyama M. HMG-CoA reductase inhibitor has protective effects against stroke events in stroke-prone spontaneously hypertensive rats. Stroke. 2003;34:157-163.
29. Di Napoli M, Papa F. The proteasome system and proteasome inhibitors in stroke: controlling the inflammatory response. Curr Opin Invest Drug. 2003;4:1333-1342.
30. Hassan A, Hunt BJ, O'Sullivan M, Parmar K, Bamford JM, Briley D, Brown MM, Thomas DJ, Markus HS. Markers of endothelial dysfunction in lacunar infarction and ischaemic leukoaraiosis. Brain. 2003;126:424-432.
31. Schmidt R, Fazekas F, Enzinger C, Ropele S, Kapeller P, Schmidt H Risk factors and progression of small vessel disease-related cerebral abnormalities. J Neural Transm Suppl. 2002;47-52.
32. Elbaz A, Poirier O, Moulin T, Chedru F, Cambien F, Amarenco P. Association between the Glu298Asp polymorphism in the endothelial constitutive nitric oxide synthase gene and brain infarction. Stroke. 2000;31:1634-1639.